biosafety4u.berlin GmbH and Z.A.S. Zentral Archiv Service GmbH create joint cooperation in cell biobanking
Berlin, Neubrandenburg, 19 May 2023
biosafety4u.berlin GmbH, a service provider for genetic engineering facilities in Germany, and Z.A.S. Zentral Archiv Service GmbH, a Rhenus company specialized in archiving and biobanking in compliance to GLP and GMP regulations, announce today the creation of a joint cooperation to establish a holistic service offer for external cell biobanking in a regulatory context.
Z.A.S cell biobanking capabilities can help clients to maintain a long-term storage of valuable production cell lines for a variety of applications:
- Master cell banks (MCB) / Working cell banks (WCB) for GMP production of biopharmaceuticals including monoclonal antibodies and peptide/protein based biosimilars and/or originators, virus-based gene therapeutics, and vaccines. Applicable both for human and animal therapeutic use.
- Advanced Therapy Medicinal Products (ATMP) intended for human use e.g., like human blood products, human stem cell-based products, living biotherapeutics like bacteria, or phage-based disinfectants or therapeutics.
- Master cell banks (MCB) / Working cell banks (WCB) to produce cell culture-derived novel food and food ingredients e.g., like Pichia pastoris production lines, cellular agriculture cell lines of animal or plant origin, irrespective of a genetical modification.
„This partnership will enable our clients to benefit from a broader service portfolio “, says Christian Lange, Quality Manager GLP and GCLP @ biosafety4u.berlin GmbH. He has also been approved by the local competent authority as external Biosafety Officer for Z.A.S. Zentral Archiv Service according to §29 GenTSV (German Act for Genetic Engineering).
Dr. Benjamin Bader, Managing Director @ Z.A.S. Zentral Archiv Service GmbH, adds: „Regulated biobanking can be troublesome due to continuously changing and increasing demands on safety aspects. Together with biosafety4u.berlin we provide a full spectrum biobanking service to our clients now including safety assessments and consultation”.
Weitere Informationen enthält der von BioSafety4U und Z.A.S. verfasste Trendletter: ZAS_BioSafety4U_Partnership_2023.PDF
